AC
SRNE

Aristides Capital’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Aristides Capital’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-24,302
Closed -$271K – 185
2020
Q3 		$271K Buy
+24,302
New +$222K 0.19% 74

Other funds holding SRNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Aristides Capital's SRNE Position: Q4 2020 in Review

Aristides Capital sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2020, closing a stake of 24,302 shares — an estimated $271K sold.

Aristides Capital first reported a position in SRNE in Q3 2020 and held it in 1 quarter. The position peaked at $271K in Q3 2020. 219 funds tracked by Wall St. Rank hold SRNE as of Q4 2020.

  • Aristides Capital reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Aristides Capital sold 24,302 Sorrento Therapeutics, Inc. shares in Q4 2020, an estimated $271K.
  • Aristides Capital first reported a position in Sorrento Therapeutics, Inc. in Q3 2020 and held it in 1 quarter.
  • Aristides Capital's Sorrento Therapeutics, Inc. position peaked at $271K in Q3 2020.
  • 219 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2020.

Based on Aristides Capital's 13F filing for Q4 2020, filed 12 Feb 2021.